ESMO Asia 2016

The 2nd European Society for Medical Oncology (ESMO) Asia congress took place on 16–19 December 2016 at the Suntec Singapore Convention & Exhibition Centre, Singapore.

Boehringer Ingelheim hosted a satellite symposium entitled ‘NSCLC treatment updates: Connecting evidence to clinical practice’, which was held on Saturday 17 December 2016, 18:00–19:20. The meeting was chaired by Prof. Ross Soo and included presentations from Prof. Daniel Tan and Prof. Solange Peters.

In addition to the symposium, an oral presentation on the overall survival analysis from the LUX-Lung 7 trial and a poster describing the analysis of tumour and serum biomarkers in the LUX-Lung 8 trial were presented. See below for further details.

The full ESMO Asia 2016 programme can be found here.

Boehringer Ingelheim ESMO Asia 2016 satellite symposium

NSCLC treatment updates: Connecting evidence to clinical practice

Saturday 17 December 2016, 18:00–19:20

Summit 2 Hall, Suntec Singapore
Convention & Exhibition Centre, Singapore



Prof. Ross Soo
National University Cancer Institute Singapore
Prof. Daniel Tan
National Cancer Centre Singapore
Prof. Solange Peters
Centre Hospitalier Universitaire Vaudois (CHUV) Lausanne, Switzerland


18:00 – 18:10

Welcome, introductions and opening presentation

Ross Soo

18:10 – 18:35

Treatment choice in EGFR mutation-positive NSCLC

(presentation, case studies and panel discussion)

First-line irreversible ErbB family blockade

Ross Soo

18:35 – 18:45

First-line treatment resistance: Mechanisms and treatment implications

Daniel Tan

18:45 – 18:55

Panel discussion: discussing the evidence

Panel led by Ross Soo

18:55 – 19:15

ErbB family blockade in advanced squamous cell carcinoma (SCC): Clinical insights (presentation, case studies and panel discussion)

Solange Peters

19:15 – 19:20

Final questions, summary and meeting close

Ross Soo

Click here to view the invite.